Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,...
Reexamination Certificate
2005-11-08
2005-11-08
Stucker, Jeffrey (Department: 1648)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
C424S136100, C424S178100, C424S182100, C424S193100
Reexamination Certificate
active
06962701
ABSTRACT:
Disclosed are methods for vaccine priming, using co-treatment, at a temporally similar or at a previous time, with a priming antibody capable of priming, or enhancing, or potentiating the effects of a vaccine, or vaccine composition. Also disclosed are methods of using this process to prevent or treat disease.
REFERENCES:
patent: 5824307 (1998-10-01), Johnson
patent: WO 99/61065 (1999-12-01), None
Byers “What Can Randomized Controlled Trials Tell Us About Nutrition and Cancer Prevention?”, CA Journal, vol. 49, No. 6, (Nov./Dec. 1999), pp. 353-361.
Bellone et al. “Cancer immunotherapy: synthetic and natural peptides in the balance”, Immunology Today, vol. 20, No. 10 (1999), pp. 467-462.
Gura, “Systems for Identifying New Drugs Are Often Faulty”, Science, vol. 278 (Nov. 1997), pp. 1041-1042.
Riffkin et al. AA single amino-acid change between the antigenically different extracellular serine proteases V2 and B2 from Dichelobacter nodosus@, Gene, vol. 167 (1995), pp. 279-283.
Abaza et al. AEffects of amino acid substitutions outside an antigenic site on protein binding to monoclonal antibodies of predetermined specificity obtained by peptide immunization@, Journal of Protein Chemistry, vol. 11, No. 5, (1992), pp 433-444.
Cruse et al. Illustrated Dictionary of Immunology (Boca Raton, FL, CRC Press, Inc., 1995), p. 309. QR180.4.C78.
Paul, Fundamental Immunology, (Philadelphia & New York, Lippincott-Raven Publishers, 1993), pp. 250 and 1311-1312. QR181.F84.
Peter Seiler, et al, Induction of Protective Cytotoxc T Cell Responses in the Presence of High Titers of Virus-Neutralizing Antibodies: Implications for Passive and Active Imuunization, J. Exp. Med., The Rockfeller University Press, vol 187, No. 4, 649-654, Feb. 16, 1998.
James E. Crowe, Jr., et al. Cold-passaged, temperature-sensitive mutants of human respiratory syncytial virus (RSV) are highly attenuated, immunogenic, and protective in seronegative chimpanzees, even when RSV antibodies are infused shortly before immunization, Respiratory Viruses Section, Laboratory of Infectious Diseases, Vaccine 1995 vol. 13 No. 9 Dec. 5, 1994.
Medimmune Inc.
Medimmune, Inc.
Stucker Jeffrey
LandOfFree
Methods of priming the immunogenic activity of vaccines... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of priming the immunogenic activity of vaccines..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of priming the immunogenic activity of vaccines... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3473197